Potential anti-respiratory syncytial virus lead compounds from Aglaia species

Pharmazie

Volumn 63, Issue 10, 2008, Pages 768-773

  Esimone, C O ^a,c   Eck, G ^b   Duong, T N ^d   Uberla K ^a   Proksch, P ^b   Grunwald, T ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF NIGERIA   (Nigeria)

^d INSTITUTE OF CHEMISTRY   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXY 25 METHOXY 3,4 SECODAMMARA 4(28),23 DIENE 3 CARBOXYLIC ACID; 20,24 DIHYDROXY 3,4 SECODAMMARA 4(28),25 DIENE 3 CARBOXYLIC ACID; 20,25 DIHYDROXY 3,4 SECODAMMARA 4(28),23 DIENE 3 CARBOXYLIC ACID; 24 EPOXY 25,26,27 TRISNOR 24 OXO 3,4 SECO 4(28) DAMMAREN 3 CARBOXYLIC ACID; 24,25 DIHYDROXY 5ALPHA DAMMAR 20 ENE 3 ONE; 24,25 EPOXY CYCLOARTAN 3 OL; 24,25 EPOXY DAMMAR 20 ENE 3 ONE; 29 NOR CYCLOARTENOL; 31 NOR CYCLOARTENOL; 4ALPHA,14 DIMETHYL 9,19 CYCLOCHOLESTAN 3BETA,24ALPHA,25 TRIOL; AGLAIOL; ANTIVIRUS AGENT; APHIDICOLIN; CABRALEONE; DAMMARENOLIC ACID; EICHLERIANIC ACID; LUPEOL; LUPEONE; METHYLDAMMARENOLATE; NILOTICIN; OCOTILLONE; PISCIDINOL A; SHOREIC ACID; UNCLASSIFIED DRUG;

AGLAIA; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ISOLATION; DRUG POTENCY; HEP 2 CELL; HUMAN; HUMAN CELL; METHYLATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS REPLICATION;

AGLAIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KINETICS; PLAQUE ASSAY; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TETRAZOLIUM SALTS; THIAZOLES;

EID: 54149090237     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.8563     Document Type: Article

References (44)

1. Aiken C, Chen CH (2005) Betulinic acid derivatives as HIV-1 antivirals. Trends Mol Med 11: 31-36.
2. Bohnenstengel FI, Steube KG, Meyer C, Nugroho BW, Hung PD, Kiet LC, Proksch P (1999) Structure activity relationships of antiproliferative rocaglamide derivatives from Aglaia species (Meliaceae). Z Naturforsch 54: 55-60.
3. Chanock RM, Parrott RH (1996) Acute respiratory disease in infancy and childhood: present understanding and prospects for prevention. Pediatrics 36: 21-39.
4. Cianci C, Meanwell N, Krystal M (2005) Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother 55: 289-292.
5. Cianci C, Yu K, Combrink K, Sin N, Pearce B, Wang A, Civiello R, Voss S, Luo G, Kadow K, Genovesi EV, Venables B, Gulgeze H, Trehan A, James J, Lamb L, Medina I, Roach J, Yang Z, Zadjura L, Colonno R, Clark J, Meanwell N, Krystal M (2004) Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Ag Chemother 48: 413-422.
6. Cowan MM (1999) Plant products as antimicrobial agents. Clin Microbiol Rev 12: 564-582.
7. Curreli F, Friedman-Kien AE, Flore O (2005) Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest 115: 642-652.
8. Dargan DJ, Subak-Sharpe JH (1992) The antiviral activity of triterpenoid compounds. Semin Virol 3: 31-40.
9. De Clercq E (2000) Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev 20: 323-349.
10. Dowell SF, Anderson LJ, Gary HEJ, Erdman DD, Plouffe JF, File TMJ, Marston BJ, Breiman RF (1996) Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis 174: 456-462.
11. Englund JA, Sullivan CJ, Jordan MC, Dehner LP, Vercellotti GM, Balfour HH (1988) Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 109: 203-208.
12. Evers M, Poujade C, Soler F, Ribeill Y, James C, Lelievre Y, Gueguen JC, Reisdorf D, Morize I, Pauwels R, De Clercq E, Henin Y, Bousseau A, Mayaux JF, LePecq JB, Dereu N (1996) Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action. J Med Chem 39: 1059-1068.
13. Falsey AR, Treanor JJ, Betts RF, Walsh EE (1992) Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc 40: 115-119.
14. Falsey AR, Walsh EE (2000) Respiratory syncytial virus infection in adults. Clin Microbiol Rev 13: 371-384.
15. Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, Jiang JB, Janzen WP, Chen IS, Lee KH (1994) Anti-AIDS Agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 57: 243-247.
16. Garcia R, Raad I, Abi-Said D, Bodey G, Champlin R, Tarrand J, Hill LA, Umphrey J, Neumann J, Englund J, Whimbey E (1997) Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. Infect Control Hosp Epidemiol 18: 412-416.
17. Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140: 543-546.
18. Heikkinen T, Thint M, Chonmaitree T (1999) Prevalence of various respiratory viruses in the middle ear during acute otitis media. New Engl J Med 340: 260-264.
19. Huntley CC, Weiss WJ, Gazumyan A, Buklan A, Feld B, Hu W, Jones TR, Murphy T, Nikitenko AA, O'Hara B, Prince G, Quartuccio S, Raifeld YE, Wyde P, O'Connell JF (2002) RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother 46: 841-847.
20. Jassim SA, Naji MA (2003) Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol 95: 412-427.
21. Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, Goto T, Sano K, Nakashima H (2001) Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 45: 1225-1230.
22. Kim HW, Arrobio JO, Brandt CD, Jeffries BC, Pyles G, Reid JL, Chanock RM, Parrot RH (1973) Epidemiology of RSV infection in Washington, D.C. Importance of virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol 98: 216-225.
23. Kimura K, Mori S, Tomita K, Ohno K, Takahashi K, Shigeta S, Terada M (2000) Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antivir Res 47: 41-51.
24. Kneyber MCJ, Mou HA, Groot RD (2000) Treatment and prevention of respiratory virus infection. Eur J Pediatr 159: 339-411.
25. Lafeuillade A, Hattinger G, Chadapaud S (2001) Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357: 280-281.
26. Lipipun V, Kurokawa M, Suttisri R, Taweechotipatr P, Pramyothin P, Hattori M, Shiraki K (2003) Efficacy of Thai medicinal plant extracts against herpes simplex virus type 1 infection in vitro and in vivo. Antivir Res 60: 175-180.
27. Martin MA, Bock MJ, Pfaller MA, Wenzel RP (1988) Respiratory syncytial virus infections in adult bone marrow transplant recipients. Lancet i: 1396-1397.
28. Mathur U, Bentley DW, Hall CB (1980) Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. Ann Intern Med 93: 49-52.
29. Mizushina Y, Lida A, Ohta K, Sugawara F, Sakaguchi K (2000) Novel triterpenoids inhibit both DNA polymerase and DNA topoisomerase. Biochem J 350: 757-763.
30. Moyse E, Lyon M, Cordier G, Mornex JF, Collet L, Froehlich P (2000) Viral RNA in middle ear mucosa and exudates in patients with chronic otitis media with effusion. Arch Otolaryngol Head Neck Surg 126: 1105-1110.
31. Murry AR, Dowell SF (1997) Respiratory syncytial virus: not just for kids. Hosp Pract 15: 87-88.
32. Nishino H, Nishino A, Takayasu J, Hasegawa T, Iwashima A, Hirabayashi K, Iwata S, Shibata S (1988) Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. Cancer Res 48: 5210-5215.
33. Pannell CM (1992) A taxonomic monograph of the genus Aglaia Lour. (Meliaceae). Kew Bulletin Additional Series XVI, Royal Botanic Gardens, Kew. HMSO, London, p. 1-379.
34. Perry LM (1980) Medicinal plants of East and Southeast Asia. MIT Press, Cambridge, MA.
35. Poehland BL, Carte BK, Francis TA, Hyland LJ, Allaudeen HS, Troupe N (1987) In vitro antiviral activity of dammar resin triterpenoids. J Nat Prod 50: 706-713.
36. Prince GA (2001) An update on respiratory syncytial virus antiviral agents. Expert Opin Investig Drugs 10: 297-308.
37. Robertson SE, Roca A, Alonso P, Simoes EAF, Kartasasmita CB, Olaleye DO, Odaibo GN, Collinson M, Venter M, Zhu Y, Wright P (2004) Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. Bull W.H.O. 82: 914-922.
38. Seetharama RKS, Narayana K (2005) In vivo chromosome damaging effects of an inosine monophosphate dehydrogenase inhibitor: Ribavirin in mice. Indian J Pharmacol 37: 90-95.
39. Selwyn BJ (1990) The epidemiology of acute respiratory tract infections in young children: Comparison of findings from several developing countries. Rev Infect Dis 12: S870-S888.
40. Sudo K, Konno K, Watanabe W, Shigeta S, Yokota T (2001) Mechanisms of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028). Microbiol Immunol 45: 531-537.
41. Sun HD, Qiu SX, Lin LZ, Wang ZY, Lin ZW, Pengsuparp T, Pezzuto JM, Fong HH, Cordell GA, Farnsworth NR (1996) Nigranoic acid, a triterpenoid from Schisandra sphaerandra that inhibits HIV-1 reverse transcriptase. J Nat Prod 59: 525-527.
42. Ternette N, Tippler B, Uberla K, Grunwald T (2007) Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 25: 7271-7279.
43. Treanor J, Falsey A (1999) Respiratory viral infections in the elderly. Antivir Res 44: 79-102.
44. Vlietinck AJ, Vanden Berghe DA (1991) Can ethnopharmacology contribute to the development of antiviral drugs? J Ethnopharmacol 32: 141-153.